share_log

The Foundation Assar Gabrielsson Prize Recipients 2024 Awarded

The Foundation Assar Gabrielsson Prize Recipients 2024 Awarded

2024 年阿薩爾·加布里爾森基金會獎獲得者頒發
PR Newswire ·  05/16 12:33

GOTHENBURG, Sweden, May 16, 2024 /PRNewswire/ -- Assar Gabrielsson was one of the founders of Volvo. In accordance with his wishes, a fund was established for clinical research of cancer diseases. The fund has existed since 1962. It primarily supports research projects that are considered promising but have not yet reached the weight that provides funding from major research funds.

瑞典哥德堡,2024年5月16日 /PRNewswire/ — 阿薩爾·加布里爾森是沃爾沃的創始人之一。根據他的意願,設立了一個癌症疾病臨床研究基金。該基金自1962年以來一直存在。它主要支持被認爲有前景但尚未達到主要研究基金資助的權重的研究項目。

The Assar Gabrielsson Foundation has awarded Anna Wenger as the winner in the basic science research category and Sara Bjursten as the winner in the clinical research category. The prize recipients are rewarded with SEK 100,000 each as extra research grants, administered by the Sahlgrenska Academy at the University of Gothenburg.

阿薩爾·加布里爾森基金會授予安娜·溫格爲基礎科學研究類別的獲勝者,薩拉·比爾斯滕爲臨床研究類別的獲勝者。獲獎者每人將獲得10萬瑞典克朗作爲額外研究補助金,由哥德堡大學薩爾格倫斯卡學院管理。

"Anna Wenger is awarded the prize in the category of basic science research for advanced basic science studies on malignant gliomas in children and adults. The studies provide new knowledge about epigenetic differences and cancer stem cells different types of glioma. The results can be of great benefit for the development of better diagnostics and choice of treatment for patients with glioma," says Eva Forssell-Aronsson, professor at the University of Gothenburg and executive member of the Assar Gabrielsson Foundation in the citation.

“安娜·溫格因對兒童和成人惡性神經膠質瘤的高級基礎科學研究而獲得基礎科學研究類別的獎項。這些研究提供了有關表觀遺傳學差異和癌症幹細胞不同類型的神經膠質瘤的新知識。哥德堡大學教授、阿薩爾·加布里爾森基金會執行成員伊娃·福塞爾-阿隆森在引文中說,這些結果可以爲神經膠質瘤患者開發更好的診斷方法和治療選擇。

"Sara Bjursten receives the award in the category of clinical research for clinically important and well-conducted research regarding immunotherapy in cancer patients. The studies provide new knowledge about side effects in the central nervous system, especially with regard to T cells and biomarkers in the blood. The results may lead to new strategies for early detection of side effects in these patients," says Professor Eva Forssell-Aronsson.

“薩拉·比爾斯滕因有關癌症患者免疫療法的臨床重要且進行良好的研究而獲得臨床研究類別的獎項。這些研究提供了有關中樞神經系統副作用的新知識,尤其是與血液中的T細胞和生物標誌物有關的新知識。這些結果可能會爲早期發現這些患者的副作用提供新的策略。” 伊娃·福塞爾-阿隆森教授說。

Journalists who want further information, please contact:

想了解更多信息的記者,請聯繫:

Torbjörn Holmström, Chairman of the Assar Gabrielssons Foundation, 031 66 10 73, or Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation, 070 372 26 26.

阿薩爾·加布里爾森基金會主席托爾布約恩·霍爾姆斯特羅姆,031 66 10 73,或阿薩爾·加布里爾森基金會執行成員伊娃·福塞爾-阿隆森,070 372 26 26。

For more information, please visit volvogroup.com For frequent updates, follow us on X: @volvogroup

欲了解更多信息,請訪問 volvogroup.com 如需頻繁更新,請在 X 上關注我們: @volvogroup

The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers' uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs more than 100,000 people and serves customers in almost 190 markets. In 2023, net sales amounted to SEK 553 billion (EUR 48 billion). Volvo shares are listed on Nasdaq Stockholm.

沃爾沃集團通過運輸和基礎設施解決方案推動繁榮,提供卡車、公共汽車、建築設備、船舶和工業應用的動力解決方案、延長客戶正常運行時間和生產力的融資和服務。沃爾沃集團成立於1927年,致力於塑造可持續交通和基礎設施解決方案的未來格局。沃爾沃集團總部位於瑞典哥德堡,擁有超過10萬名員工,爲近190個市場的客戶提供服務。2023 年,淨銷售額爲 5,530 億瑞典克朗(480 億歐元)。沃爾沃股票在斯德哥爾摩納斯達克上市。

This information was brought to you by Cision

這些信息是由 Cision 帶給你的

The following files are available for download:

以下文件可供下載:

Press Release - The Foundation Assar Gabrielsson Prize recipients 2024 awarded

AssarGabrielsson 23

新聞稿-2024年阿薩爾·加布里爾森基金會獎獲得者頒發

AssarGabrielsson 23

SOURCE AB Volvo

來源 AB Volvo

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論